Robertson Stephens Wealth Management LLC Grows Position in Pfizer Inc. $PFE

Robertson Stephens Wealth Management LLC raised its position in Pfizer Inc. (NYSE:PFE) by 33.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,071 shares of the biopharmaceutical company’s stock after purchasing an additional 7,962 shares during the quarter. Robertson Stephens Wealth Management LLC’s holdings in Pfizer were worth $777,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter worth about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley dropped their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.35.

Pfizer Price Performance

PFE stock opened at $24.81 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82. The stock’s 50 day moving average is $24.86 and its two-hundred day moving average is $24.13. The company has a market capitalization of $141.03 billion, a PE ratio of 13.19, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.